Currently, enhancement of cholinergic neurotransmission via cholinesterase inhibitors
represents the main available approach to treat cognitive and behavioural symptoms of the …

AD is a progressive neurodegenerative disorder and a leading cause of dementia in an
aging population worldwide. The enormous challenge which AD possesses to global …

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases that
affect millions of people worldwide, with both prevalence and incidence increasing with age …

Tau neuronal and glial pathologies drive the clinical presentation of Alzheimer's disease
and related human tauopathies. There is a growing body of evidence indicating that …

Schizophrenia remains a challenging disease to treat effectively with current antipsychotic
medications due to their limited efficacy across the entire spectrum of core symptoms as well …

Neurodegenerative diseases are a major public health problem worldwide with a wide
spectrum of symptoms and physiological effects. It has been long reported that the …

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder whose aetiology is
still unknown. Most hypotheses point out the gut-brain axis as a key factor for IBS. The axis is …

Background Successful development of agents that improve cognition and behavior in
Alzheimer's disease (AD) is critical to improving the lives of patients manifesting the …

Emerging research has re-emphasized the role of the cortical cholinergic system in the
symptomology and progression of Alzheimer's disease (AD). Basal forebrain (BF) …

Alzheimer's disease involves many neurobiological alterations from molecular to
macroscopic spatial scales, but we currently lack integrative, mechanistic brain models …